Strides Pharma Science Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Strides Pharma Science’s record carries an unqualified audit opinion every year since FY21, yet the balance sheet is shaped by forces that sit outside the profit-and-loss account: a ₹1,248.87 crore unacknowledged claim, ₹1,157.56 crore of corporate guarantees, and a decade-long habit of restructuring through court-approved schemes that generate large one-off gains. The goodwill on the books has never been impaired despite a ₹172.72 crore write-down on acquired US assets and a ₹799.83 crore loss at associate Stelis that left the Group’s ₹377.68 crore investment untouched.

Key findings

  1. Goodwill and intangible assets have been a persistent Key Audit Matter since FY2019, yet no goodwill impairment has ever been recorded Major - Goodwill impairment testing has been flagged as a Key Audit Matter in every consolidated report from FY2019 through FY2026. The Group recorded a ₹172.72 crore impairment on acquired US manufacturing assets in FY2022, yet consolidated goodwill of ₹529.4 crore as at 31 March 2024 has never been impaired. Associate Stelis Biopharma posted a ₹799.83 crore loss in FY2023, but the Group assessed no impairment on its ₹377.68 crore investment; for the Stelis CDMO CGU in FY23, the value-in-use would equal carrying value if the discount rate increased by 17.46%.
  2. Strides repeatedly uses NCLT schemes to reshape its balance sheet, generating large one-off gains while overriding standard accounting dates Major - The demerger of the CDMO and Softgel business to OneSource, effective 27 November 2024 with appointed date 1 April 2024, generated a gain on disposal of ₹3,188.1 crore credited to the profit-and-loss account. The auditor drew an Emphasis of Matter, a special call-out in the audit report, that this retrospective accounting “overrides the relevant requirement of Appendix A to Ind AS 10”. Separately, a fair-value gain of ₹102.1 crore was booked as an exceptional item in FY2025 when an equity interest in OneSource ceased to be equity-accounted.
  3. A multi-year pattern of covenant breaches requires lender waivers Major - The Group did not meet certain financial covenants in FY22 and obtained temporary relaxations from lenders; the Company and its subsidiaries repeated this in FY24. Associate Stelis also breached covenants in FY22 and FY23 and requested lender relaxations. Trade receivables of ₹565.88 crore carried recourse bill discounting as at 31 March 2023, with the corresponding liability recorded in short-term borrowings.
  4. Revenue quality is pressured by product-withdrawal provisions, a persistent gross-to-net KAM, and a sharp contraction in Access Markets Minor - The auditor has flagged chargebacks, rebates, returns, and related accruals as a Key Audit Matter in every annual report from FY21 through FY26. Provisions for ranitidine withdrawal and a testosterone recall together totalled ₹20 crore in the nine months to December 2025. Access Markets revenue fell 52% year-on-year to ₹128.6 crore in FY26, which management attributed to the variability of tender-based sales.
  5. Audit opinions are consistently unqualified, but the audit trail was not fully enabled at the database level in FY24 and FY25 Minor - The statutory auditor issued an unqualified opinion on the consolidated and standalone financial statements every year from FY21 through FY26. In FY25, the audit trail facility “was not enabled at the database level to log any direct data changes” in the holding company’s consolidation software for part of the year. In FY24, the audit trail was not enabled at the database level for the general ledger and consolidation software, and the auditor could not comment on the payroll software trail.
  6. The group operates through an exceptionally large web of over 100 subsidiaries, with constant in-year incorporations, divestments, and restructurings Minor - In FY25, the group’s regulatory filing listed over 100 wholly owned subsidiaries across jurisdictions including Yemen, Syria, Iran, and North Korea. That same year, 27 subsidiaries with total assets of ₹2,548.7 crore and revenues of ₹378.4 crore were unaudited by any auditor. In FY26 alone, the group completed a stake acquisition in Neviton Softech, increased its holding in an African entity, proposed a new demerger scheme, and divested or deregistered entities in Cyprus and South Africa.
  7. Founder Arun Kumar moved to non-executive roles while his son was elevated, and promoter pledges fell from 52% to 27.3% Minor - Promoter pledge stood at 27.27% in the latest year, down from 51.97% a year earlier. Arun Kumar transitioned from Executive Chairperson to Non-Executive Director and Chairperson effective 5 April 2025. His son Aditya was appointed Executive Director from 1 June 2024, with remuneration rising from ₹1.00 crore in FY24 to ₹2.42 crore in FY26. Three promoter-group entities were reclassified to public during FY26, and the company reported one instance of insider-trading code violation in FY26 and two in FY25.

What to watch

Bottom line: This is a disclosed and audited record with an unbroken chain of clean opinions. The character of the risk is structural rather than hidden: a ₹1,248.87 crore unacknowledged claim sits off the balance sheet, goodwill that has never been impaired is tested against narrowing headroom, and court-approved schemes routinely route material gains around operating profit. Watch the resolution of the unacknowledged claim, the next round of impairment tests, and whether the audit trail gaps close in FY27.